⚠️
Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Interchange of vaccine products
13,185 total reports2.1% serious outcomes
Share
13,185
Total Reports
41
Deaths
241
Hospitalizations
2.1
Severity Rate
% serious outcomes
About Interchange of vaccine products Reports
Interchange of vaccine products has been reported 13,185 times in VAERS from 1990 to 2026.
Of these reports, 41 were associated with death (0.31%) and 241 involved hospitalization.
The overall serious outcome rate (death or hospitalization) for reports mentioning Interchange of vaccine products is 2.1%.
Understanding Interchange of vaccine products in VAERS
•Temporal association only: These reports show Interchange of vaccine products occurred after vaccination, not necessarily because of vaccination.
•Background rates matter: Many symptoms occur naturally at baseline rates in the population, unrelated to vaccination.
•Reporting variability: Medical terminology may be used differently by various healthcare providers and over time.
•Investigation needed: High-frequency reports may trigger further epidemiological studies to determine causation.
What This Data Shows
Most Associated Vaccines: The vaccines most frequently mentioned in reports with Interchange of vaccine products. This may reflect usage patterns, not causation.
Severity Patterns: The percentage of reports that involve serious outcomes can help prioritize safety investigations.
Reporting Trends: Changes in reporting frequency over time may reflect increased awareness, media attention, or actual safety signals.
Most Associated Vaccines
1. COVID1915,002
2. HPV9418
3. UNK197
4. COVID19-2182
5. HPV4141
6. MENB132
7. HEP131
8. FLU445
9. FLUX40
10. RV136
Quick Facts
Reports:13,185
Deaths:41
Hospitalizations:241
Mortality Rate:0.31%
Severity Rate:2.1%
Related Analysis
Explore Further
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.